CXCL10 and COVID-19: Interestingly, the recent study of Raza MT et al. found that TMPRSS2 and the cytokine CXCL10 resulted over and co-expression in prostate cancer and COVID-19, and that they can represent two putative biomarkers responsible for the increased vulnerability and fatality of prostate cancer patients to COVID-19 [35].